OrbitonOpen research workspace →
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

TSX:CRDLLive AI agent

Cardiol Therapeutics Inc.

Investor website: https://www.cardiolrx.com/

About

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, and the ARCHER Program studied CardiolRx™ specifically in acute myocarditis. The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure.

Verified company data

Cash position
$83.9M
Shares outstanding
118.93m
Fully diluted shares
120.66m
Projects
["CardiolRx™ (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. CardiolRx™ is pharmaceutically manufactured under cGMP to meet the highest standards for product purity, consistency, and stability. A Phase I safety and pharmacokinetic study of single and multiple ascending doses of CardiolRx™ was completed and demonstrated that CardiolRx™ was safe and generally well tolerated at all dose levels, with no serious adverse events reported. The results supported the Company’s two Investigational New Drug Application authorizations from the United States Food and Drug Administration to conduct two Phase II studies in rare heart diseases: recurrent pericarditis and acute myocarditis. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis.","CRD-38 is a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. We are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care. We are currently developing CRD-38 that is intended to improve the pharmacokinetic profile compared to existing formulations. Subcutaneous administration has the potential to allow for a lower dose of drug to be delivered with less frequent administration, while achieving the same or greater therapeutic effect. Our research collaborators have shown that cannabidiol, when administered subcutaneously, is effective in a pre-clinical model of heart failure. The subcutaneous approach is practical and widely used in human medicine although the formulation requires specific characteristics. We have successfully developed a formulation that meets these required characteristics. Currently, this formulation is undergoing pharmacokinetic testing."]
Leadership
David Elsley (CEO, Experienced leader in the biopharmaceutical industry with a focus on cardiovascular therapies.), Andrew Hamer (CFO, Financial executive with a strong background in corporate finance and strategic planning.), Chris Waddick (Chief Development Officer, Over 20 years of experience in drug development and regulatory affairs.), Guillermo Torre-Amione (Chief Medical Officer, Renowned cardiologist with extensive experience in clinical research and patient care.), Colin Stott (Chief Operating Officer, Operations expert with a history of managing large-scale pharmaceutical projects.), Bernard Lim (Director, Experienced in corporate governance and strategic advisory roles.), Stephen Nicholls (Director, Cardiovascular expert with a focus on innovative therapies.), Antonio Abbate (Director, Renowned cardiologist with a focus on heart failure and clinical trials.), Stefano Toldo (Director, Expert in cardiovascular medicine and clinical research.), Dennis McNamara (Director, Experienced in clinical development and regulatory strategy.), Leslie Cooper (Director, Cardiologist with a focus on heart disease and clinical research.), Arvind Bhimaraj (Director, Expert in cardiology and clinical trials.), Wai Hong Wilson Tang (Director, Renowned cardiologist with expertise in heart failure.), Peter Liu (Director, Experienced in clinical research and cardiology.), Carsten Tschope (Director, Cardiologist with a focus on heart failure and clinical trials.), Matthias Friedrich (Director, Expert in cardiovascular imaging and research.), Edimar Bocchi (Director, Renowned cardiologist with a focus on heart failure.), Yaron Arbel (Director, Experienced in clinical research and cardiology.), Mathieu Kerneis (Director, Expert in cardiovascular medicine.), Jennifer Chao (Director, Experienced in clinical research and regulatory affairs.), Allen Luis (Director, Expert in corporate finance and strategy.), Allan Klein (Director, Experienced in clinical research and cardiology.), Paul Cremer (Director, Expert in cardiovascular medicine and clinical trials.), Peter Pekos (Director, Experienced in corporate governance and strategic advisory roles.), Teri Loxam (Director, Expert in clinical research and regulatory affairs.), John Geddes (Director, Experienced in clinical research and cardiology.), Tim Garnett (Director, Expert in cardiovascular medicine and clinical trials.), Anne Tomalin (Director, Experienced in corporate governance and strategic advisory roles.), Dor Lotan (Director, Expert in clinical research and cardiology.), Tom Wang (Director, Experienced in clinical research and cardiology.), Mohamed Al Kazaz (Director, Expert in cardiovascular medicine.), Andrea Parker (Director, Experienced in clinical research and regulatory affairs.), Dan Crandall (Director, CPA with expertise in corporate finance.), Joseph Hill (Director, Renowned cardiologist with a focus on heart disease.), Bruce McManus (Director, Expert in cardiovascular research and clinical trials.), Paul Ridker (Director, Renowned cardiologist with a focus on cardiovascular disease prevention.)

Verified data last updated:

Recent filings

Investor FAQ

About Cardiol Therapeutics Inc. (TSX:CRDL)